# Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer

> **NCT02553928** · PHASE4 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 62 (actual)

## Conditions studied

- Alzheimer Dementia (AD)

## Interventions

- **DRUG:** Memantine (once daily)
- **DRUG:** Memantine (twice daily)

## Key facts

- **NCT ID:** NCT02553928
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2019-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02553928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02553928, "Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02553928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*